Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact

Cancer Patients Warned about Marijuana Claims

by Brayton Purcell LLP | Dec 6, 2017 | Asbestos

marijuana oil and leaves

Medical marijuana has been recommended by satisfied users – that marijuana is effective in helping people with cancer, including mesothelioma, deal with pain.

But the Food & Drug Administration has announced it cannot support all the other claims made about the therapeutic use of pot. This warning applies especially to businesses that are pushing marijuana-based products, with the idea that marijuana can actually shrink or eliminate tumors.

The warning

On November 15, the FDA issued a harsh warning to those engaging in deceptive advertising. FDA Commissioner Scott Gottlieb then held a press conference in which he castigated companies that prey on terminally ill people with claims that marijuana can make tumors disappear altogether.

“We will not going to look the other way when it comes to marijuana containing products,” Gottlieb said

The status of marijuana in the eyes of the U.S. government has not changed. It is still classed as a Schedule I controlled substance. Against this classification are 28 states and the District of Columbia that have passed laws allowing the use of marijuana to treat serious medical conditions.

Cannabis oils

Regulators zeroed in particularly on those who market cannabidiol, a marijuana derivative sold as oils, syrups, capsules, teas and even topical lotions.

There are reports by victims of mesothelioma that they have been using cannabidiol and claim it is effective in slowing or stopping the growth of cancer cells.

The FDA says it has no reports of cannabidiol being this effective. One study, conducted at California Pacific Medical Center found the substance actually stopped cancer metastasis in laboratory and animal testing. But no research on human beings has confirmed that finding.

‘The FDA report did not question marijuana’s effectiveness in addressing the pain, anxiety and nausea cancer patients suffer.

Recent Posts

  • Boiler Room Workers and Asbestos Exposure
  • Mitigating the financial impact of mesothelioma treatments
  • The EPA’s difficulty with data disclosure
  • Judge orders EPA to close loopholes on asbestos-related reporting
  • Department of Veterans Affairs Increases Pension Rate for 2021

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us